Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Post Pumps Up Nutrition Activity With Nestle’s PowerBar, Musashi Brands

This article was originally published in The Tan Sheet

Executive Summary

The cereal giant is bulking up its Active Nutrition Group and targeting annualized revenues of $550 million in the nutrition and weight loss sector. Post also continues diversifying its revenues with the deal.

You may also be interested in...



Post Expects Stronger Nutrition Business Value To Emerge On Its Own, Plans IPO

Planned IPO of 25% of shares in nutrition business targets unlocking value currently held down by Post's other units. Its competitors in cereal space as well as firms across broader food industry also may determine their acquired nutritional businesses could be higher valued operating separately.

Cereal Firm Post Expands Into Supplements With Premier Nutrition Pick-Up

Seeking to diversify its portfolio for more dramatic sales growth, Post Holdings acquires Premier Nutrition, maker of Joint Juice and Premier Protein supplements. The $180 million transaction follows closely Post’s purchase of probiotic bar and natural cereal maker Attune Foods.

Nestle China JV Backs Nutritional And Rx Botanical Development

Nestle Health Science and Chi-Med’s joint venture Nutrition Science Partners creates an opportunity to develop and commercialize scientifically validated botanical nutritionals and drugs, based in part on Chi-Med’s traditional Chinese medicine library of 1,200 plants and 50,000 extracts.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS107372

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel